ClinicalTrials.gg
Sign In

Biological

Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1 clinical trials

studies test it
3
open now
1
in phase 3
0
first study started
2018

Keep track of what changes. Save the Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

MB-CART20.1
3
CD20-targeting CAR T cells
3
Anti-CD20 CAR T cells
3

Studies by the year they started

3 studies that test it; most in 2018 (1)

Studies that test Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1, by start year
YearStudies
20181
20191
20241

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
1
Phase 2
1
No phase
1

What it is tested for

Each study’s main condition, where its own words name it.

Melanoma
2
Lymphoma, B-Cell
1

Who runs them

Industry 3 · Other 0

Miltenyi Biomedicine GmbH (3)

Often tested with

Tested in the same studies.

Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1 (1) · Zamtocabtagene autoleucel (1)

Studies

Open first, then newest update. How each study uses Autologous Anti-CD20 CAR Transduced CD4/CD8 Enriched T-cells MB-CART20.1 is read from its arms, and is right about nine times in ten.

Testing it · 3